Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer

Journal of Thoracic Disease

Volumn 5, Issue 2, 2013, Pages

  Randall, J Michael ^a   Bharne, Anjali A ^b   Bazhenova, Lyudmila A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cedars Sinai Medical Group   (United States)

Author keywords

Adjuvant chemotherapy; Carboplatin; Cisplatin; Hypersensitivity; Lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PACLITAXEL; PEMETREXED;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PREMEDICATION; TACHYCARDIA; URTICARIA;

EID: 84876789118     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.06.12     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
3. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
4. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
5. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
6. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
7. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141-5.
8. Morgan JS, Adams M, Mason MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 1994;30A:1205-6.
9. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005;15:13-8.
10. Cleare MJ, Hughes EG, Jacoby B, et al. Immediate (type I) allergic responses to platinum compounds. Clin Allergy 1976;6:183-95.
11. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006;103:608-13.
12. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.
13. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Publish date June 14, 2010. Available online: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-_ QuickReference_8.5x11.pdf (accessed 2012 Jan 31).
14. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129-33.
15. DeMoor PA, Matusov Y, Kelly C, et al. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer 2011;2:153-64.
16. Gadducci A, Tana R, Teti G, et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18:615-20.
17. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007;105:81-3.
18. Sugimoto H, Iwamoto T, Murashima Y, et al. Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. Cancer Chemother Pharmacol 2011;67:415-19.
19. Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011;122:226-32.
20. Markman M, Zanotti K, Kulp B, et al. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003;89:514-6.
21. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414-20.
22. Saunders MP, Denton CP, O'Brien ME, et al. Hypersensitivity reactions to cisplatin and carboplatin-a report on six cases. Ann Oncol 1992;3:574-6.
23. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611-4.
24. Syrigou E, Makrilia N, Vassias A, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful.? Anti- Cancer Drugs 2010;21:333-8.
25. Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009;123:1262-7.e1.